$BPMC
Blueprint Medicines Corp

2021 Q1 Form 10-Q Financial Statement

#000155837021005262 Filed on April 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $21.58M $6.167M
YoY Change 249.86% 744.79%
Cost Of Revenue $102.0K $24.00K
YoY Change 325.0%
Gross Profit $21.47M $6.143M
YoY Change 249.57%
Gross Profit Margin 99.53% 99.61%
Selling, General & Admin $42.00M $35.66M
YoY Change 17.8% 115.4%
% of Gross Profit 195.59% 580.42%
Research & Development $79.71M $84.15M
YoY Change -5.27% 13.33%
% of Gross Profit 371.19% 1369.79%
Depreciation & Amortization $1.608M $1.571M
YoY Change 2.36% 33.36%
% of Gross Profit 7.49% 25.57%
Operating Expenses $121.7M $119.8M
YoY Change 1.6% 31.94%
Operating Profit -$100.2M -$113.7M
YoY Change -11.81%
Interest Expense $700.0K $2.900M
YoY Change -75.86%
% of Operating Profit
Other Income/Expense, Net $524.0K $2.703M
YoY Change -80.61% 1.39%
Pretax Income -$99.71M -$111.0M
YoY Change -10.17% 27.0%
Income Tax
% Of Pretax Income
Net Earnings -$99.71M -$111.0M
YoY Change -10.13% 26.94%
Net Earnings / Revenue -462.15% -1799.14%
Basic Earnings Per Share -$1.72
Diluted Earnings Per Share -$1.72 -$2.106M
COMMON SHARES
Basic Shares Outstanding 58.02M 54.03M
Diluted Shares Outstanding 58.02M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $852.0M $666.8M
YoY Change 27.78% 60.32%
Cash & Equivalents $698.0M $375.2M
Short-Term Investments $154.0M $291.6M
Other Short-Term Assets $25.90M $10.10M
YoY Change 156.44% -5.61%
Inventory $16.03M $2.665M
Prepaid Expenses
Receivables $34.66M $4.510M
Other Receivables $0.00 $0.00
Total Short-Term Assets $937.7M $704.7M
YoY Change 33.07% 65.22%
LONG-TERM ASSETS
Property, Plant & Equipment $32.99M $37.82M
YoY Change -12.77% -64.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $578.2M $83.70M
YoY Change 590.8%
Other Assets $5.360M $10.38M
YoY Change -48.37% -5.63%
Total Long-Term Assets $687.7M $208.9M
YoY Change 229.13% 24.47%
TOTAL ASSETS
Total Short-Term Assets $937.7M $704.7M
Total Long-Term Assets $687.7M $208.9M
Total Assets $1.625B $913.6M
YoY Change 77.91% 53.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.889M $8.468M
YoY Change -65.88% 92.45%
Accrued Expenses $86.48M $73.96M
YoY Change 16.93% 43.37%
Deferred Revenue $14.88M $8.690M
YoY Change 71.19%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $112.4M $98.29M
YoY Change 14.4% 55.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.355M $7.928M
YoY Change -7.23% -94.16%
Total Long-Term Liabilities $7.355M $7.928M
YoY Change -7.23% -94.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $112.4M $98.29M
Total Long-Term Liabilities $7.355M $7.928M
Total Liabilities $225.4M $230.7M
YoY Change -2.31% 31.55%
SHAREHOLDERS EQUITY
Retained Earnings -$731.1M -$1.056B
YoY Change -30.78%
Common Stock $58.00K $54.00K
YoY Change 7.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.400B $682.9M
YoY Change
Total Liabilities & Shareholders Equity $1.625B $913.6M
YoY Change 77.91% 67.73%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$99.71M -$111.0M
YoY Change -10.13% 26.94%
Depreciation, Depletion And Amortization $1.608M $1.571M
YoY Change 2.36% 33.36%
Cash From Operating Activities -$125.8M -$109.3M
YoY Change 15.05% 36.34%
INVESTING ACTIVITIES
Capital Expenditures $173.0K $1.525M
YoY Change -88.66% -13.84%
Acquisitions
YoY Change
Other Investing Activities $132.4M $61.40M
YoY Change 115.64% -32.6%
Cash From Investing Activities $132.2M $59.86M
YoY Change 120.84% -32.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.609M
YoY Change -21.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.011M 310.2M
YoY Change -97.74% 15322.68%
NET CHANGE
Cash From Operating Activities -125.8M -109.3M
Cash From Investing Activities 132.2M 59.86M
Cash From Financing Activities 7.011M 310.2M
Net Change In Cash 13.43M 260.7M
YoY Change -94.85% 2240.68%
FREE CASH FLOW
Cash From Operating Activities -$125.8M -$109.3M
Capital Expenditures $173.0K $1.525M
Free Cash Flow -$126.0M -$110.9M
YoY Change 13.62% 35.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57793533
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58277412
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001597264
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37359
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
BLUEPRINT MEDICINES CORPORATION
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3632015
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
45 Sidney Street
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2021Q1 dei City Area Code
CityAreaCode
617
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
374-7580
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
BPMC
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58341527
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
697966000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
684636000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
153995000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
187213000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34662000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7096000
CY2021Q1 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
9201000
CY2020Q4 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
18213000
CY2021Q1 us-gaap Inventory Net
InventoryNet
16030000
CY2020Q4 us-gaap Inventory Net
InventoryNet
8581000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25856000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22020000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
937710000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
927759000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
578168000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
677873000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32991000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34129000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65987000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67539000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5171000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5360000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5925000
CY2021Q1 us-gaap Assets
Assets
1625387000
CY2020Q4 us-gaap Assets
Assets
1718393000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2889000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4370000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86479000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105938000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8193000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7935000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14876000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12559000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
112437000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
130802000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
79477000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
81669000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26097000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28599000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7355000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7235000
CY2021Q1 us-gaap Liabilities
Liabilities
225366000
CY2020Q4 us-gaap Liabilities
Liabilities
248305000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58277412
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57793533
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
58000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
58000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2136130000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2106600000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5097000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5214000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-731070000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-631356000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1400021000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1470088000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1625387000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1718393000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
21576000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6167000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
102000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79710000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84146000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42002000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35655000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
121814000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
119825000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
738000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2904000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-214000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-201000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
524000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2703000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-99714000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-110955000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-400000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2492000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
517000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99597000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108490000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58023000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52655000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1470088000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8318000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21212000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
117000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-99714000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1400021000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
464359000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1613000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17026000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
308423000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2465000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-110955000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
682931000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-99714000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-110955000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1608000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1571000
CY2021Q1 bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
1522000
CY2020Q1 bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
1391000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20684000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16859000
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
536000
CY2020Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-134000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27613000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3847000
CY2021Q1 bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
-9013000
CY2020Q1 bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
-2152000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4837000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
382000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2594000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1408000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
44000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
66000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1464000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3715000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-20785000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-16576000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-185000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-575000
CY2021Q1 bpmc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1905000
CY2020Q1 bpmc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1073000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-125778000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109328000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1525000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
83080000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
139250000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
215450000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
200635000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
132197000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59860000
CY2020Q1 bpmc Proceeds From Issuance Of Common Stock Net Of Underwriting Discounts Commissions And Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsCommissionsAndOfferingExpenses
308541000
CY2021Q1 bpmc Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan
NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan
7011000
CY2020Q1 bpmc Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan
NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan
1609000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7011000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310150000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13430000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
260682000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
689804000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119604000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-97000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
703137000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380336000
CY2020Q1 bpmc Stock Issuance Costs Incurred But Not Yet Paid Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredButNotYetPaidNoncashOrPartialNoncashTransaction
118000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
443000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
465000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
574000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
697966000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375168000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5171000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
703137000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380336000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Blueprint Medicines Corporation (the Company), a Delaware corporation incorporated on October 14, 2008, is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company’s approach is to leverage its novel target discovery engine to systematically and reproducibly identify kinases that are drivers of diseases and to craft highly selective and potent drug candidates that may provide significant and durable clinical responses for patients without adequate treatment options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has two approved precision therapies and is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. The Company is devoting substantially all of its efforts to research and development for current and future drug candidates and commercialization of AYVAKIT/AYVAKYT, GAVRETO and any current or future drug candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, the Company had cash, cash equivalents and marketable securities of $1,430.1 million. Based on the Company’s current operating plans, the Company anticipates that its existing cash, cash equivalents and marketable securities will <span style="background-color:#ffffff;color:#212529;">be sufficient to enable it to fund its current operations for at least the next twelve months from the issuance of the financial statements. </span></p>
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1430100000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: revenue recognition, inventory, operating lease right-of-use assets, operating lease liabilities, stock-based compensation expense, accrued expenses, and income taxes. The length of time and full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, subject to change and difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact thereof on local, regional, national and international customers and markets. The Company considers the impact of COVID-19 while making the estimates within its consolidated financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
731603000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
643000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
83000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
732163000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
864138000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
962000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
865086000
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
12
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
169000000.0
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
125700000
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q1 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
59
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
578200000
CY2020Q4 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
65
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
677900000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
215500000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
200600000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1192000
CY2019Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
0
CY2021Q1 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
1582000
CY2020Q1 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
607000
CY2021Q1 us-gaap Contract With Customer Asset Allowance For Credit Loss Recovery
ContractWithCustomerAssetAllowanceForCreditLossRecovery
774000
CY2020Q1 us-gaap Contract With Customer Asset Allowance For Credit Loss Recovery
ContractWithCustomerAssetAllowanceForCreditLossRecovery
119000
CY2021Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2000000
CY2020Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
488000
CY2021Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2000000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1192000
CY2021Q1 bpmc Inventory Current And Noncurrent Work In Process Net Of Reserves
InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves
16243000
CY2020Q4 bpmc Inventory Current And Noncurrent Work In Process Net Of Reserves
InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves
9488000
CY2021Q1 bpmc Inventory Current And Noncurrent Finished Goods Net Of Reserves
InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves
1000000
CY2020Q4 bpmc Inventory Current And Noncurrent Finished Goods Net Of Reserves
InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves
914000
CY2021Q1 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
17243000
CY2020Q4 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
10402000
CY2021Q1 us-gaap Inventory Net
InventoryNet
16030000
CY2020Q4 us-gaap Inventory Net
InventoryNet
8581000
CY2021Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
1213000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1821000
CY2021Q1 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
17243000
CY2020Q4 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
10402000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
5200000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5200000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54287000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53860000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21296000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19731000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32991000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34129000
CY2021Q1 us-gaap Depreciation
Depreciation
1600000
CY2020Q1 us-gaap Depreciation
Depreciation
1600000
CY2021Q1 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
56049000
CY2020Q4 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
60255000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11327000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27622000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11797000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10986000
CY2021Q1 bpmc Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss
AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1649000
CY2020Q4 bpmc Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss
AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
966000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5657000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6109000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86479000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105938000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6030641
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.28
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
755639
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
100.26
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257309
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
32.31
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
142578
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
73.23
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6386393
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
66.79
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3279897
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
55.07
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
133200000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M23D
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20700000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16900000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21212000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
17026000
CY2021Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
528000
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
167000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20684000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16859000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20684000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16859000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7988000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7755000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4722000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4381000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
327000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
722000
CY2021Q1 us-gaap Lease Cost
LeaseCost
4395000
CY2020Q1 us-gaap Lease Cost
LeaseCost
3659000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3696000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3581000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
523000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082

Files In Submission

Name View Source Status
0001558370-21-005262-index-headers.html Edgar Link pending
0001558370-21-005262-index.html Edgar Link pending
0001558370-21-005262.txt Edgar Link pending
0001558370-21-005262-xbrl.zip Edgar Link pending
bpmc-20210331.xsd Edgar Link pending
bpmc-20210331x10q.htm Edgar Link pending
bpmc-20210331x10q_htm.xml Edgar Link completed
bpmc-20210331xex10d1.htm Edgar Link pending
bpmc-20210331xex31d1.htm Edgar Link pending
bpmc-20210331xex31d2.htm Edgar Link pending
bpmc-20210331xex32d1.htm Edgar Link pending
bpmc-20210331_cal.xml Edgar Link unprocessable
bpmc-20210331_def.xml Edgar Link unprocessable
bpmc-20210331_lab.xml Edgar Link unprocessable
bpmc-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending